Improved post-transplant outcomes following inotuzumab ozogamicin-based salvage therapy in relapsed/refractory B-ALL: a real-world retrospective study
{{output}}
Relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) remains challenging, and allogeneic hematopoietic cell transplantation (allo-HCT) is often the only curative option. Inotuzumab ozogamicin (InO) has demonstrated high remission rates in sal... ...
